<DOC>
	<DOCNO>NCT00037713</DOCNO>
	<brief_summary>This trial design test impact adjuvant BEC2 ( 2.5 mg ) /BCG vaccination survival patient LD Small Cell Lung Cancer ( SCLC ) . Patients stratified institution , KPS ( 60 - 70 % v 80 - 100 % ) , response first line combine modality therapy ( CR v PR ) consist least 2 drug regimen ( 4 - 6 cycle ) chest radiotherapy regimen . Patients randomize one two treatment arm : standard arm ( Observational cohort ) best supportive care , treatment arm ( 5 intradermal vaccination BEC2 ( 2.5 mg ) + BCG give day 1 week 0 , 2 , 4 , 6 , 10 .</brief_summary>
	<brief_title>Survival Randomized Phase III Trial Patients With Limited Disease ( LD ) Small Cell Lung Cancer Vaccinated With Adjuvant BEC2 BCG</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Small Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histocytologically proven SCLC Limited disease diagnosis Age great equal 18 Patients clinical response CR PR first line combine modality therapy KPS great equal 60 Adequate bone marrow , liver heart function Written inform Consent Prior surgical treatment SCLC History tuberculosis NCIC CTG grade 3 local skin toxicity reaction ( ulceration ) &gt; IU PPD test &gt; 5 IU HIV positive Splenectomy spleen radiation therapy medical history Prior therapy proteins murine origin Any second line therapy SCLC Investigational agent immune therapy within 4 week prior study randomization Severe active infection Active infection require systemic antibiotic , antiviral , antifungal treatment Serious unstable chronic illness The use systemic antihistamine , NSAID systemic corticosteroid Any previous malignancy except adequately treat CIS cervix non melanoma skin cancer previous malignancy 5 year prior sign recurrence Pregnancy breast feed absence adequate contraception fertile patient Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition assess patient randomization trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>LD Small Cell Lung Cancer</keyword>
	<keyword>BEC2 , vaccine</keyword>
	<keyword>adjuvant , monoclonal antibody</keyword>
	<keyword>LD Small Cell Lung Cancer ( VA Classification , Zelen , 1973 )</keyword>
</DOC>